Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients with Pseudomonas Aeruginosa (Pa)
Status:
RECRUITING
Trial end date:
2026-05-05
Target enrollment:
Participant gender:
Summary
A Phase 1/2a, Multi-Centre, Randomised, Open-label study to assess the safety, tolerability, PK, and efficacy of RESP30X in Adult NCFB participants with confirmed high-titre respiratory PPMs.